Cervical cancer, the fourth most common cancer type in women, causes approximately 350,000 deaths each year, mainly in middle- and low-income countries. Human papillomavirus (HPV) infection is known… read more.
Public health messaging that drives stigma around Pre-exposure Prophylaxis (PrEP), a medication that can reduce HIV risk by up to 99%, appears to play a role in uptake… read more.
Bavarian Nordic A/S has submitted clinical data to the European Medicines Agency (EMA) to support the extension of the Imvanex (MVA-BN ) smallpox and mpox vaccine indication to… read more.
Pfizer Inc. announced positive top-line safety and immunogenicity results from sub-study B of the ongoing pivotal Phase III clinical trial ( NCT05842967 ) MONeT (RSV I Mmunizati ONStudy… read more.
The Dengue vaccine has an efficacy rate of over 50% in reducing disease cases, with lasting effects and a very good safety profile. This is confirmed by the first global meta-analysis on the efficacy of TAK-003, better… read more.
Vir Biotechnology is cutting one-quarter of its workforce in a move away from infectious disease research. The company, which rose to prominence with its coronavirus antibody work in… read more.
Bavarian Nordic A/S announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a type II… read more.
GSK plc announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has shared 48-week findings from the PASO… read more.
Gilead Sciences, Inc announced its program for the upcoming 25th International AIDS Conference (AIDS 2024), taking place in Munich, Germany, and virtually, from July 22-26. As the leading… read more.
Merck, known as MSD outside of the United States and Canada, announced upcoming data presentations and programming at the 25th International AIDS Conference (AIDS 2024), taking place July 22-26,… read more.
New research led by Oregon Health & Science University reveals a promising approach to developing a universal influenza vaccine — a so-called “one and done” vaccine that confers… read more.
Women who receive vaccination against respiratory syncytial virus (RSV) during late pregnancy in order protect a newborn do not have an increased risk of preterm birth, researchers reported… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
